|
References [1] Jack Bowden and Ekkehard Glimm. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal, 50:515–527,2008. [2] Shein-Chung Chow and Mark Chang. Adaptive Design Methods in Clin- ical Trials. Chapman and Hall/CRC, 2007. [3] Lu Cui, H. M. James Hung, and Sue-Jane Wang. Modification of sample size in group sequential clinical trials. Biometrics, Vol. 55, No. 3:853–857,1999. [4] FDA. Guide for Industry. 2010. [5] K. K. Gordon Lan, Yuhwen Soo, Cynthia Siu, and Mey Wang. The use of weighted z-tests in medical research. Journal of Biopharmaceutical Statistics, 15:625–639, 2005. [6] Gang Li, Weichung J. Shih, Tailiang Xie, and Jiang Lu. A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics, 3,2:277–287, 2002. [7] Sue-Jane Wang, H. M. James Hung, and Robert T. ONeill. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal, 51:358–374, 2009. [8] Sue-Jane Wang, Robert T. ONeill, and H.M.James Hung. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics, 6:227–244, 2007. [9] Peter Bauer and Franz Koenig. The reassessment of trial perspectives from interim data - critical view. Statistics in Medicine, 25:23–36, 2006.
|